Inventiva SA logo

Inventiva SA

IVA
Healthcare|Biotechnology|France
$4.29
-0.21 (-4.66%)

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 1.65, 20.47, 119.77, 377.87, 844.17 ], "ebit_estimate": [ -108.44, -110.33, -39.35, 27.44, 244.4 ], "ebitda_estimate": [ -127, -92.86, -48.21, -127.88, null ], "net_income_estimate": [ -162.47, -185.58, -174.45, 4.93, 304.18 ], "per_share_eps_estimate": [ -0.82, -0.9, -0.72, -0.36, 0.73 ], "eps_nri_estimate": [ -0.77, -0.9, -0.72, -0.36, 0.73 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 1.28, null, null, null, null ], "pretax_income_estimate": [ -165.25, -204.17, -150.49, 8.69, 325.68 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 85, 85, 90, 90, 95 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 5.87 ], "long_term_growth_rate_mean": 27.33, "long_term_revenue_growth_rate_mean": "230.41", "future_per_share_eps_estimate_growth": 27.79, "future_eps_nri_estimate_growth": 27.33, "future_revenue_estimate_growth": 230.41, "future_ebit_estimate_growth": 34.54, "future_ebitda_estimate_growth": 47.22, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 21.46, "future_pretax_income_estimate_growth": 24.25, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }
quarterly
{ "date": [ "202606", "202612", "202706", "202712" ], "revenue_estimate": [ null, null, null, null ], "ebit_estimate": [ -85.4, -93.11, -94.39, -102.36 ], "ebitda_estimate": [ null, null, null, null ], "net_income_estimate": [ -85.4, -93.11, -94.39, -102.36 ], "per_share_eps_estimate": [ -0.32, -0.35, -0.33, -0.31 ], "eps_nri_estimate": [ -0.32, -0.35, -0.33, -0.31 ], "dividend_estimate": [ null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null ], "pretax_income_estimate": [ -85.4, -93.11, -94.39, -102.36 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null ], "roa_estimate": [ null, null, null, null ], "roe_estimate": [ null, null, null, null ], "gross_margin_estimate": [ null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null ], "pettm_estimate": [ 0, 0, 0, null ], "long_term_growth_rate_mean": 27.33, "long_term_revenue_growth_rate_mean": "230.41", "future_per_share_eps_estimate_growth": 27.79, "future_eps_nri_estimate_growth": 27.33, "future_revenue_estimate_growth": 230.41, "future_ebit_estimate_growth": 34.54, "future_ebitda_estimate_growth": 47.22, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 21.46, "future_pretax_income_estimate_growth": 24.25, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }